A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2028

Conditions

Advanced Esophageal Carcinoma

Interventions

DRUG

chidamide+Camrelizumab+Apatinib

DRUG

Irinotecan or Docetaxel or Paclitaxel

Irinotecan Docetaxel Paclitaxel

Trial Locations (1)

Peking University Cancer Hospital, Beijing

All Listed Sponsors

lead

Peking University

OTHER